OCM
ALNY icon

Orion Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Orion Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$649K Sell
2,155
-700
-25% -$211K 0.2% 78
2026
Q1 		$945K Sell
2,855
-112
-4% -$38.1K 0.33% 51
2025
Q4 		$1.18M Sell
2,967
-173
-6% -$76.6K 0.4% 42
2025
Q3 		$1.43M Sell
3,140
-100
-3% -$40.7K 0.5% 36
2025
Q2 		$1.06M Sell
3,240
-100
-3% -$27.7K 0.4% 45
2025
Q1 		$902K Hold
3,340
– – 0.38% 47
2024
Q4 		$786K Sell
3,340
-85
-2% -$22.4K 0.35% 53
2024
Q3 		$942K Sell
3,425
-150
-4% -$39.1K 0.46% 44
2024
Q2 		$869K Sell
3,575
-100
-3% -$15.8K 0.46% 41
2024
Q1 		$549K Hold
3,675
– – 0.29% 65
2023
Q4 		$703K Hold
3,675
– – 0.41% 50
2023
Q3 		$651K Sell
3,675
-300
-8% -$57.2K 0.42% 48
2023
Q2 		$755K Hold
3,975
– – 0.5% 47
2023
Q1 		$796K Sell
3,975
-30
-0.7% -$6.31K 0.53% 40
2022
Q4 		$952K Sell
4,005
-170
-4% -$36.3K 0.7% 32
2022
Q3 		$836K Sell
4,175
-1,690
-29% -$322K 0.67% 36
2022
Q2 		$855K Sell
5,865
-700
-11% -$99.3K 0.66% 37
2022
Q1 		$1.07M Sell
6,565
-100
-2% -$15.2K 0.65% 37
2021
Q4 		$1.13M Sell
6,665
-10
-0.1% -$1.86K 0.64% 38
2021
Q3 		$1.26M Hold
6,675
– – 0.76% 35
2021
Q2 		$1.13M Hold
6,675
– – 0.7% 38
2021
Q1 		$942K Hold
6,675
– – 0.66% 43
2020
Q4 		$868K Buy
+6,675
New +$891K 0.64% 42

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Orion Capital Management's ALNY Position: Q2 2026 in Review

Orion Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 25% in Q2 2026, selling an estimated $211K and leaving 2,155 shares worth $649K. The position accounts for 0.2% of the portfolio, ranked #78.

Orion Capital Management first reported a position in ALNY in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.43M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Orion Capital Management held 2,155 shares of Alnylam Pharmaceuticals worth $649K as of Q2 2026.
  • Orion Capital Management sold 700 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $211K.
  • Alnylam Pharmaceuticals made up 0.2% of Orion Capital Management's portfolio in Q2 2026, its #78 holding.
  • Orion Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Orion Capital Management's Alnylam Pharmaceuticals position peaked at $1.43M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Orion Capital Management's 13F filing for Q2 2026, filed 18 Aug 2026.